Abstract
Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pathophysiological implications of TKs in the digestive tract include changes in TK innervation, in the expression of TKs and TK receptors, which result in inflammation- and immune-induced disturbances of gut functions, such as dysmotility (diarrhoea/constipation), secretory diarrhoea and visceral hyperalgesia. Increasing evidence correlates all these TKergic system abnormalities with gastrointestinal diseases of different etiology (i.e. inflammatory bowel diseases, irritable bowel syndrome). Accordingly, TK receptors have been identified as novel targets for the development of new therapeutic agents for clinical use. Available preclinical findings have shown that TK antagonists could counteract the most significant symptoms characterizing these gut diseases.
Keywords: neurokinin A, peristalsis, immunoreactivity, idiopathic chronic constipation, pyloric sphincter, Irritable bowel syndrome
Current Drug Targets
Title: Tachykinins: Role in Human Gastrointestinal Tract Physiology and Pathology
Volume: 7 Issue: 8
Author(s): Giovanna Improta and Maria Broccardo
Affiliation:
Keywords: neurokinin A, peristalsis, immunoreactivity, idiopathic chronic constipation, pyloric sphincter, Irritable bowel syndrome
Abstract: Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pathophysiological implications of TKs in the digestive tract include changes in TK innervation, in the expression of TKs and TK receptors, which result in inflammation- and immune-induced disturbances of gut functions, such as dysmotility (diarrhoea/constipation), secretory diarrhoea and visceral hyperalgesia. Increasing evidence correlates all these TKergic system abnormalities with gastrointestinal diseases of different etiology (i.e. inflammatory bowel diseases, irritable bowel syndrome). Accordingly, TK receptors have been identified as novel targets for the development of new therapeutic agents for clinical use. Available preclinical findings have shown that TK antagonists could counteract the most significant symptoms characterizing these gut diseases.
Export Options
About this article
Cite this article as:
Improta Giovanna and Broccardo Maria, Tachykinins: Role in Human Gastrointestinal Tract Physiology and Pathology, Current Drug Targets 2006; 7 (8) . https://dx.doi.org/10.2174/138945006778019354
DOI https://dx.doi.org/10.2174/138945006778019354 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aceruloplasminemia
Current Drug Targets The Guinea Pig as an Animal Model for Asthma
Current Drug Targets Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology The Value of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Anxiety Disorders: An Integrative Review
CNS & Neurological Disorders - Drug Targets Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Impaired Functional Connectivity of the Thalamus in Alzheimer’ s Disease and Mild Cognitive Impairment: A Resting-State fMRI Study
Current Alzheimer Research The Brainstem Tau Cytoskeletal Pathology of Alzheimer’s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance
Current Alzheimer Research Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Challenges in Diagnosing Cerebral Lacunar Infarcts
Current Medical Imaging Kappa Opioids, Salvinorin A and Major Depressive Disorder
Current Neuropharmacology Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation
Current Drug Targets Early-phase 18F-AV-45 PET Imaging can Detect Crossed Cerebellar Diaschisis Following Carotid Artery Stenosis and Cerebral Hypoperfusion
Current Neurovascular Research Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Spreading Depolarization Waves in Neurological Diseases: A Short Review about its Pathophysiology and Clinical Relevance
Current Neuropharmacology Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies
Current Alzheimer Research Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
CNS & Neurological Disorders - Drug Targets Current Status of Tyrosine Hydroxylase in Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Fibromyalgia: Mechanisms, Current Treatment and Animal Models
Current Pharmaceutical Biotechnology